Follow The Filings

TGTX TG Therapeutics Inc.

Health Care, filed as TG THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 2.7%
  • $29M

Who owns this now

Largest portfolio weights among holders, up to 2.7% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman 2.7%

Who owns TGTX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 2.7% Hold 535,000 $29M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TGTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TGTX insider trades
  • None no insider bought on the open market
  • $438K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Laurence N Charney Director
    Sale
    $275K 5,000 shares at $54.96 2.9% of stake
    Traded Sep 10 Filed Sep 14
    ↗
  2. Yann Echelard Director
    Sale
    $163K 5,000 shares at $32.57 2.2% of stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 gifts and 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
DEF 14A FORM DEF 14A Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
10-K FORM 10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q FORM 10-Q Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $233.66M $329M $616.29M
Net income $12.67M $23.38M $447.18M
Net margin * 5.4% 7.1% 72.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $317.94M $566.36M $630.76M
Total non-current assets * $11.64M $11.33M $432.49M
Total assets $0.33B $0.578B $1.06B
Total current liabilities $53.72M $90.68M $153.76M
Total non-current liabilities * $115.36M $264.65M $261.47M
Total equity $160.5M $222.36M $648.02M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$31.41M -$40.52M -$24.77M
Cash from investing -$50.65M -$1.04M $13.8M
Cash from financing $72.7M $128.53M -$89.73M
Net change in cash -$9.36M $86.97M -$100.7M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.